SightLife Surgical announced that Bob Stevens has joined the company as its first Chief Technology Officer. In his new position, Bob will lead all product research and development, ensuring that the right product portfolio supports the overall business strategy.
“There is no one better suited than Bob to help SightLife Surgical improve corneal care worldwide,” William Link, PhD, SightLife Surgical board chair, said in a company news release. “The depth of his experience will not only build our research and development capacity, but will also help shape our entire business strategy moving forward.”
Previously, Bob worked at Novartis/Alcon Laboratories for nearly 35 years. During his tenure, he spent more than 20 years leading all research and design for surgical products in the field of ophthalmology. The technology he helped bring to market significantly impacted the practice of medicine and positioned Alcon as the leading company in manufacturing of ophthalmic surgical products. Bob introduced several industry-leading innovations, including a proprietary intraocular lens material, AcrySof, along with proprietary intraocular lens designs, Viscoelastics and surgical instruments for both anterior and posterior segment surgery.
“SightLife Surgical’s success hinges on delivering proven innovations to corneal surgeons worldwide,” Monty Montoya, CEO and president of SightLife Surgical, said in a company news release. “Bob’s leadership, technical experience and business savvy will undoubtedly help us to identify and bring the most efficacious treatments and products to market.”
“I am honored to join the SightLife Surgical team,” Mr. Stevens said. “I look forward to bringing a new perspective to this growing organization and contributing to its mission to eliminate corneal blindness by 2040.”
Bob’s experience in eye banking dates back to 1991 when he received the Thoth Award for his role in developing a plan to support U.S. eye banks during a crisis involving cornea preservative storage media. The storage media used by 80 percent of the market was recalled due to bacterial contamination, but the plan Bob developed with partners prevented a shut down of the corneal transplant business in the U.S. Bob has served on the University of Washington Eye Institute Community Action Board for the last 5 years. He earned his bachelor’s degree in medical technology and his master’s degree in clinical microbiology from the University of Washington.